Clinical Assessment of the Effectiveness and Safety of Herpes Patch SOS in the Treatment of Herpes Simplex Labialis in Comparison to a Competitor's Product.

Clinical Assessment of the Effectiveness and Safety of Herpes Patch SOS (Hansaplast®) Based on Hydrocolloids Without Active Substances in the Treatment of Herpes Simplex Labialis in Comparison to a Competitor's Product (Herpes Vesicle Patch of COMPEED®)

Recent clinical studies showed, that a hydrocolloid patch is effective, well tolerated and comparable with aciclovir cream 5 % for the treatment of HSL lesions, while affording additional benefits of wound protection, discretion and relief of social embarrassment. The aim of the actual study was the clinical assessment of the effectiveness and safety of Hansaplast® SOS Herpes Patch (HPHP) in comparison to Compeed® Herpes Vesicle Patch (CHP) in treating HSL. Both products are CE-certificated and are available at the market for medical devices.

Inclusion Criteria:

• at least 18 years old
• with a history of recurrent HSL of the lips and/or perioral skin
• lesions typically manifesting as classical lesions
• duration of HSL symptoms not more than three days
• haven´t used acyclovir or other cold sore therapies

Exclusion Criteria:

• pregnancy
• lactating women
• women of child-bearing age without medically secured contraceptions
• topical or systemic therapy with analgesic
• anti-inflammatory or antiviral agents within the last 2 weeks
• topical therapy within the treatment area
• systemic therapy with cytostatics or immunosuppressants